-
公开(公告)号：EP2882711B1
公开(公告)日：2017-10-25
申请号：EP13827594.6
申请日：2013-07-30
IPC分类号： C07D211/46 , A61K31/4412 , A61P13/00 , A61P11/00
CPC分类号： C07D211/46
摘要： There are described new 1-alkyl-1-methyl-4-[(2,2-diphenyl-2-propoxy)acetoxy]piperidinium halides and pharmaceutical compositions comprising a 1-alkyl-1-methyl-4-[(2,2-diphenyl-2-propoxy)acetoxy]piperidinium halide as an active ingredient. These products are non-selective muscarinic acetylcholine receptor antagonists acting in the periphery and not in the brain.
-
公开(公告)号：EP3645120A1
公开(公告)日：2020-05-06
申请号：EP18824955.1
申请日：2018-06-28
IPC分类号： A61P25/24 , A61K45/06 , A61K31/396 , A61K31/425 , C07D498/04
-
3.发明公开
公开(公告)号：EP3347012A1
公开(公告)日：2018-07-18
申请号：EP16845102.9
申请日：2016-09-09
CPC分类号： A61K31/439 , A61K9/7023 , A61K31/216 , A61K31/4178 , A61K45/06 , A61K2300/00
摘要： A combination of a muscarinic cholinergic receptor agonist, a non-anticholinergic antiemetic agent and a non-selective, peripheral anticholinergic agent for the treatment of hypocholinergic disorders of the central nervous system.
-
4.发明公开
公开(公告)号：EP3347011A1
公开(公告)日：2018-07-18
申请号：EP16845090.6
申请日：2016-09-09
CPC分类号： A61K31/4178 , A61K31/439 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/517 , A61K45/06 , A61K2300/00 , A61P25/16 , A61P25/18 , A61P25/28
摘要： A combination of a muscarinic cholinergic receptor agonist with a non-anticholinergic antiemetic agent, and the optional addition of an acetyl choline esterase inhibitor, for the treatment of hypocholinergic disorder of the central nervous system.
-
公开(公告)号：EP3242659A1
公开(公告)日：2017-11-15
申请号：EP16735459.6
申请日：2016-01-08
IPC分类号： A61K31/216 , A61K9/70 , A61P25/28
CPC分类号： A61K31/222 , A61K9/7023 , A61K31/216 , A61K31/27 , A61K31/445 , A61K31/473 , A61K31/4748 , A61K31/55 , A61K45/06 , A61K2300/00
摘要： There is described a pharmaceutical combination comprising oxybutynin or a pharmaceutically acceptable addition salt thereof, in a transdermal therapeutic system, and an acetylcholinesterase inhibitor, useful for safely treating hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. In this combination, the acetylcholinesterase inhibitor (AChEI) is present at a dose that is higher than the maximal recommended dose, per unit form. In particular, the transdermal therapeutic system comprising oxybutynin is in combination with rivastigmine in a transdermal formulation or oral form.
-
公开(公告)号：EP2882711A1
公开(公告)日：2015-06-17
申请号：EP13827594.6
申请日：2013-07-30
IPC分类号： C07D211/40 , C07D211/54
CPC分类号： C07D211/46
摘要： There are described new 1-alkyl-1-methyl-4-[(2,2-diphenyl-2-propoxy)acetoxy]piperidinium halides and pharmaceutical compositions comprising a 1-alkyl-1-methyl-4-[(2,2-diphenyl-2-propoxy)acetoxy]piperidinium halide as an active ingredient. These products are non-selective muscarinic acetylcholine receptor antagonists acting in the periphery and not in the brain.
摘要翻译： 描述了新的1-烷基-1-甲基-4 - [（2,2-二苯基-2-丙氧基）乙酰氧基]哌啶鎓卤化物和包含1-烷基-1-甲基-4 - [（2,2 - 二苯基-2-丙氧基）乙酰氧基]哌啶鎓卤化物作为活性成分。 这些产品是非选择性的毒蕈碱乙酰胆碱受体拮抗剂，其作用于外周而不是在脑中。
-
公开(公告)号：EP2271218A1
公开(公告)日：2011-01-12
申请号：EP09726036.8
申请日：2009-03-17
CPC分类号： A61K31/46 , A61K31/27 , A61K31/325 , A61K31/445 , A61K31/473 , A61K31/4747 , A61K31/55 , A61K45/06 , A61K2300/00
摘要： There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-selective, peripheral anticholinergic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-selective, peripheral anticholinergic agent (nsPAChA) for the preparation of a pharmaceutical composition for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia and pharmaceutical compositions comprising a non-selective peripheral anticholinergic agent of formula II as illustrated in the description and an acetylcholine esterase inhibitor are also described.
-
公开(公告)号：EP3532060A1
公开(公告)日：2019-09-04
申请号：EP17866188.0
申请日：2017-10-27
IPC分类号： A61K31/47 , A61K45/06 , C07C13/615
-
公开(公告)号：EP2478099A1
公开(公告)日：2012-07-25
申请号：EP10817543.1
申请日：2010-09-13
IPC分类号： C12N15/09
CPC分类号： A61K31/439 , A61K9/0014 , A61K9/0053 , A61K9/0056 , A61K9/2018 , A61K9/205 , A61K9/2054 , A61K9/2059 , A61K9/4808 , A61K31/166 , A61K31/27 , A61K31/352 , A61K31/353 , A61K31/407 , A61K31/4178 , A61K31/4184 , A61K31/445 , A61K31/454 , A61K31/46 , A61K31/473 , A61K31/496 , A61K31/4965 , A61K31/5377 , A61K31/55 , A61K45/06 , A61K2300/00
摘要： There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetyl choline esterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HT3 receptor antagonist, a dopamine antagonist, a H1-receptor antagonist, a cannabinoid agonist, aprepitant or casopitant as an antiemetic agent and (b) an acetylcholine esterase inhibitor are also described.
-
公开(公告)号：EP2478099B1
公开(公告)日：2019-06-05
申请号：EP10817543.1
申请日：2010-09-13
IPC分类号： A61K31/4178 , A61K31/445 , A61K31/473 , A61K31/27 , A61K31/55 , A61K31/4748 , A61K9/48 , A61K9/20 , A61P25/28
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.023 秒)
